<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03400800</url>
  </required_header>
  <id_info>
    <org_study_id>MDCO-PCS-17-08</org_study_id>
    <nct_id>NCT03400800</nct_id>
  </id_info>
  <brief_title>Inclisiran for Subjects With ACSVD or ACSVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol</brief_title>
  <acronym>ORION-11</acronym>
  <official_title>A Placebo-Controlled, Double-Blind, Randomized Trial to Evaluate the Effect of 300 mg of Inclisiran Sodium Given as Subcutaneous Injections in Subjects With Atherosclerotic Cardiovascular Disease (ASCVD) or ACSVD Risk-Equivalents and Elevated Low-Density Lipoprotein Cholesterol (LDL-C)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Medicines Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Medicines Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III, placebo-controlled, double-blind, randomized study in participants with
      ASCVD or ASCVD-Risk equivalents and elevated LDL-C despite maximum tolerated dose of LDL-C
      lowering therapies to evaluate the efficacy, safety, and tolerability of subcutaneous (SC)
      inclisiran injection(s). The study will be an international multicenter study (non-United
      States).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change in LDL-C from Baseline to Day 510</measure>
    <time_frame>Baseline, Day 510</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time-adjusted Percent Change in LDL-C Levels from Baseline between Day 90 and Day 540</measure>
    <time_frame>Baseline, Day 90, Day 540</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change In LDL-C From Baseline To Day 510</measure>
    <time_frame>Baseline, Day 510</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-adjusted Absolute Change In LDL-C From Baseline Between Day 90 And Day 540</measure>
    <time_frame>Baseline, Day 90, Day 540</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) from Baseline to Day 510</measure>
    <time_frame>Baseline, Day 510</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Total Cholesterol from Baseline to Day 510</measure>
    <time_frame>Baseline, Day 510</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Apolipoprotein B (ApoB) from Baseline to Day 510</measure>
    <time_frame>Baseline, Day 510</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Non-HDL-C from Baseline to Day 510</measure>
    <time_frame>Baseline, Day 510</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1617</enrollment>
  <condition>ASCVD</condition>
  <condition>Elevated Cholesterol</condition>
  <arm_group>
    <arm_group_label>Inclisiran</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) in 1.5 milliliters (mL) will be administered as a SC injection on Day 1, Day 90, and then every 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (1.5 mL) will be administered as a SC injection of saline solution on Day 1, Day 90, and then every 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inclisiran Sodium</intervention_name>
    <description>Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.</description>
    <arm_group_label>Inclisiran</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).</description>
    <arm_group_label>Saline Solution</arm_group_label>
    <other_name>Saline Solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants may be included if they meet all of the following inclusion criteria prior to
        randomization:

          1. Male or female participants ≥18 years of age.

          2. History of ASCVD (coronary heart disease [CHD], cardiovascular disease [CVD], or
             peripheral arterial disease [PAD]).

          3. Serum LDL-C ≥1.8 millimole (mmol)/liter (L) (≥70 mg/dL).

          4. Fasting triglyceride &lt;4.52 mmol/L (&lt;400 mg/dL) at screening.

          5. Participants on statins should be receiving a maximally tolerated dose.

          6. Participants not receiving statins must have documented evidence of intolerance to all
             doses of at least 2 different statins.

          7. Subjects on lipid-lower therapies (such as a statin and/or ezetimibe) should be on a
             stable dose for ≥30 days before screening with no planned medication or dose change
             during study participation.

        Exclusion Criteria:

        Participants will be excluded from the study if any of the following exclusion criteria
        apply prior to randomization:

          1. New York Heart Association (NYHA) class IV heart failure.

          2. Uncontrolled cardiac arrhythmia.

          3. Uncontrolled severe hypertension.

          4. Active liver disease.

          5. Females who are pregnant or nursing, or who are of childbearing potential and
             unwilling to use at least 2 methods of highly effective contraception (failure rate
             less than 1% per year) (for example, combined oral contraceptives, barrier methods,
             approved contraceptive implant, long-term injectable contraception, or intrauterine
             device) for the entire duration of the study. Exemptions from this criterion:

               1. Women &gt;2 years postmenopausal (defined as 1 year or longer since last menstrual
                  period) and more than 55 years of age.

               2. Postmenopausal women (as defined above) and less than 55 years of age with a
                  negative pregnancy test within 24 hours of randomization.

               3. Women who are surgically sterilized at least 3 months prior to enrollment.

          6. Males who are unwilling to use an acceptable method of birth control during the entire
             study period (such as condom with spermicide).

          7. Treatment with other investigational products or devices within 30 days or 5
             half-lives of the screening visit, whichever is longer.

          8. Treatment (within 90 days of screening) with monoclonal antibodies directed towards
             PCSK9.

        The above information is not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ray Kausik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College of London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site 11420-002</name>
      <address>
        <city>Chomutov</city>
        <zip>43001</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11420-003</name>
      <address>
        <city>Uherské Hradiště</city>
        <zip>68601</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11049-006</name>
      <address>
        <city>Berlin</city>
        <zip>12567</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11049-002</name>
      <address>
        <city>Bochum</city>
        <zip>44787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11049-003</name>
      <address>
        <city>Frankfurt</city>
        <zip>60313</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11049-007</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11049-001</name>
      <address>
        <city>Leipzig</city>
        <zip>4103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11036-001</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11036-004</name>
      <address>
        <city>Debrecen</city>
        <zip>4025</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11036-002</name>
      <address>
        <city>Hatvan</city>
        <zip>3000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11036-003</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-018</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-079</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-016</name>
      <address>
        <city>Brzozów</city>
        <state>Podkarpackie</state>
        <zip>36-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-019</name>
      <address>
        <city>Ruda Śląska</city>
        <state>Slaskie</state>
        <zip>41-709</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-011</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-231</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-004</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-382</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-017</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-542</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-005</name>
      <address>
        <city>Gdynia</city>
        <zip>81-537</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-007</name>
      <address>
        <city>Katowice</city>
        <zip>04-040</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-012</name>
      <address>
        <city>Katowice</city>
        <zip>40-648</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-014</name>
      <address>
        <city>Kraków</city>
        <zip>31-216</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-003</name>
      <address>
        <city>Kraków</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-008</name>
      <address>
        <city>Lublin</city>
        <zip>20-709</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-001</name>
      <address>
        <city>Poznań</city>
        <zip>60-702</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-013</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-055</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-015</name>
      <address>
        <city>Tarnów</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-009</name>
      <address>
        <city>Warsaw</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-006</name>
      <address>
        <city>Warszawice</city>
        <zip>01-192</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-002</name>
      <address>
        <city>Wrocław</city>
        <zip>50-381</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-010</name>
      <address>
        <city>Wrocław</city>
        <zip>51-314</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11027-003</name>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11027-005</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1619</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11027-001</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11027-013</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7646</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11027-007</name>
      <address>
        <city>Kuilsrivier</city>
        <state>Western Cape</state>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11027-004</name>
      <address>
        <city>Somerset West</city>
        <state>Western Cape</state>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11027-006</name>
      <address>
        <city>Pretoria</city>
        <zip>184</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11027-011</name>
      <address>
        <city>Welkom</city>
        <zip>9459</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11380-005</name>
      <address>
        <city>Cherkasy</city>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11380-008</name>
      <address>
        <city>Kharkiv</city>
        <zip>61444</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11380-004</name>
      <address>
        <city>Kiev</city>
        <zip>3115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11380-009</name>
      <address>
        <city>Kiev</city>
        <zip>3115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11380-001</name>
      <address>
        <city>Kyiv</city>
        <zip>2002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11380-002</name>
      <address>
        <city>Kyiv</city>
        <zip>3037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11380-003</name>
      <address>
        <city>Kyiv</city>
        <zip>3049</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11380-007</name>
      <address>
        <city>Lviv</city>
        <zip>79060</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11380-006</name>
      <address>
        <city>Uzhhorod</city>
        <zip>8800</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-006</name>
      <address>
        <city>Edgbaston</city>
        <state>Birmingham</state>
        <zip>B15 2SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-022</name>
      <address>
        <city>Sale</city>
        <state>Cheshire</state>
        <zip>M33 2RH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-023</name>
      <address>
        <city>Sale</city>
        <state>Cheshire</state>
        <zip>M33 4BR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-021</name>
      <address>
        <city>Timperley</city>
        <state>Cheshire</state>
        <zip>WA14 5PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-012</name>
      <address>
        <city>Liskeard</city>
        <state>Cornwall</state>
        <zip>PL14 3XA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-009</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-019</name>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <zip>PL5 3JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-014</name>
      <address>
        <city>Chorley</city>
        <state>Lancashire</state>
        <zip>PR7 7NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-004</name>
      <address>
        <city>Waterloo</city>
        <state>Liverpool</state>
        <zip>L22 0LG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-027</name>
      <address>
        <city>Davyhulme</city>
        <state>Manchester</state>
        <zip>M41 7WJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-028</name>
      <address>
        <city>Bollington</city>
        <zip>SK10 5JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-026</name>
      <address>
        <city>Bury</city>
        <zip>BL9 ONJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-007</name>
      <address>
        <city>Cardiff</city>
        <zip>CF15 9SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-024</name>
      <address>
        <city>Cheadle Hulme</city>
        <zip>SK8 5LL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-010</name>
      <address>
        <city>Derby</city>
        <zip>S40 4AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-001</name>
      <address>
        <city>Glasgow</city>
        <zip>G20 0SP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-008</name>
      <address>
        <city>Hexham</city>
        <zip>NE46 1QJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-020</name>
      <address>
        <city>Macclesfield</city>
        <zip>SK11 6JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-025</name>
      <address>
        <city>Manchester</city>
        <zip>M14 6WP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-005</name>
      <address>
        <city>Manchester</city>
        <zip>M15 6SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-029</name>
      <address>
        <city>Manchester</city>
        <zip>M20 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-003</name>
      <address>
        <city>Reading</city>
        <zip>RG2 0TG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-013</name>
      <address>
        <city>Saint Austell</city>
        <zip>PL26 7RL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-002</name>
      <address>
        <city>Stockton</city>
        <zip>TS19 8PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2018</study_first_submitted>
  <study_first_submitted_qc>January 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inclisiran sodium</keyword>
  <keyword>ASCVD</keyword>
  <keyword>LDL-C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

